Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.
Mojtaba ShafiekhaniAnahita DehghaniMina ShahisavandiSeyed Ali NabavizadehMaryam KabiriAmir Hossein HassaniAbdolreza HaghpanahPublished in: Therapeutic advances in urology (2021)
One year after the prevalence of the novel coronavirus pandemic, some aspects of the physiopathology, treatment and progression of coronavirus 2019 disease (COVID-19) have remained unknown. Since no comprehensive study on the use of urological medications in patients with COVID-19 has been carried out, this narrative review aimed to focus on clinically important issues about the treatment of COVID-19 and urologic medications regarding efficacy, modifications, side effects and interactions in different urologic diseases. In this review, we provide information about the pharmacotherapeutic approach toward urologic medications in patients with COVID-19 infection. This study provides an overview of medications in benign prostatic hyperplasia, prostate cancer, impotence and sexual dysfunction, urolithiasis, kidney transplantation and hypertension as the most frequent diseases in which the patients are on long-term medications. Also, the effect of urologic drugs on the efficacy of vaccination is briefly discussed.
Keyphrases
- coronavirus disease
- prostate cancer
- sars cov
- kidney transplantation
- benign prostatic hyperplasia
- ejection fraction
- newly diagnosed
- blood pressure
- respiratory syndrome coronavirus
- mental health
- risk factors
- radical prostatectomy
- oxidative stress
- social media
- replacement therapy
- patient reported outcomes
- urinary tract
- health information